Clinigence Holdings (NUTX) AI Stock Analysis

• Market Cap: $1.21B
• Dividend Yield: N/A
• Average Volume (3M): 185.99K
• Price to Earnings (P/E): 8.2
• Beta (1Y): 1.82
• Revenue Growth: 236.03%
• EPS Growth: N/A
• Country: US
• Employees: 800
• Sector: N/A
• Sector Strength: N/A
• Industry: Medical - Healthcare Information Services
• EPS (TTM): N/A
• Shares Outstanding: 7,071,916
• 10 Day Avg. Volume: 211,562
• 30 Day Avg. Volume: 185,992
• PEG Ratio: -0.02
• Price to Book (P/B): 1.10
• Price to Sales (P/S): 0.34
• P/FCF Ratio: 7.75
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $265.00
• Price Target Upside: 138.74% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 74 Outperform
• Price Target: $203.00 ▲(82.88% Upside)

Nutex Health's strong financial performance and significant revenue growth are major positives, supported by bullish technical indicators. However, overbought signals, dependence on arbitration revenue, and legal challenges present potential risks. The stock's valuation is attractive, but the lack of a dividend yield may deter some investors.

Clinigence Holdings Business Overview & Revenue Model

Company Description

Clinigence Holdings (NUTX) is a healthcare technology company that focuses on providing innovative solutions for data management, analytics, and health information exchange. Operating primarily within the healthcare sector, Clinigence aims to enhance the quality of care and operational efficiency for healthcare providers through its advanced software platforms and services. The company's offerings include population health management tools, electronic health record (EHR) systems, and data analytics services that assist providers in improving patient outcomes and optimizing their operations.

How the Company Makes Money

Clinigence Holdings generates revenue through multiple streams, primarily by offering subscription-based services for its software platforms that help healthcare providers manage patient data and improve care coordination. The company also earns revenue from consulting services that assist healthcare organizations in implementing its technologies effectively. Additionally, partnerships with healthcare institutions and payers enhance its market reach and diversify income sources. These partnerships often lead to joint initiatives that can result in shared revenue from improved patient care outcomes and operational efficiencies.

Clinigence Holdings Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Clinigence Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 111.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUTX, the sentiment is Positive. The current price of 111 is below the 20-day moving average (MA) of 149.12, below the 50-day MA of 127.94, and above the 200-day MA of 110.95, indicating a bullish trend. The MACD of 15.10 indicates Negative momentum. The RSI at 54.94 is Neutral, neither overbought nor oversold. The STOCH value of 51.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NUTX.

Clinigence Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
NUTX	74 Outperform	$1.21B	8.25	63.86%	―	236.03%	―
HSTM	66 Neutral	$709.37M	35.04	5.87%	0.52%	3.68%	5.62%
TXG	60 Neutral	$1.99B	-25.20	-10.12%	―	1.92%	59.18%
HCAT	50 Neutral	$172.58M	-1.51	-31.33%	―	4.64%	-17.17%
EVH	48 Neutral	$454.22M	-2.57	-13.63%	―	-16.65%	-71.92%
DH	42 Neutral	$324.38M	-1.36	-47.69%	―	-5.30%	46.01%

Clinigence Holdings Corporate Events

Clinigence Holdings Files Auditors’ Consent for Nutex

Clinigence Holdings has filed an auditors’ consent related to Nutex Health Inc.’s consolidated financial statements for the years ending December 31, 2023. This filing, made on November 18, 2025, incorporates these financial statements into previously filed registration statements, potentially impacting stakeholders’ understanding of the company’s financial health.

Clinigence Holdings Granted Extension for Nasdaq Compliance

On August 20, 2025, Clinigence Holdings received a notice from Nasdaq due to a delay in filing its quarterly report for June 30, 2025, which led to non-compliance with listing requirements. The company submitted a compliance plan on October 15, 2025, and was granted an extension until December 12, 2025, to file the report, with potential delisting if not met. Nutex Health, meanwhile, reported significant growth in patient volume and cash collections for Q3 2025, with an 11.1% increase in patient visits and a 258.8% rise in cash collections compared to the previous year, driven by strategic expansions and improved revenue management.

Nutex Health Appoints New Chief Operating Officer

On September 22, 2025, Nutex Health Inc. announced the appointment of Wesley Bamburg as the new Chief Operating Officer, effective October 13, 2025. Bamburg, with 20 years of experience in healthcare operations and management, is expected to contribute significantly to Nutex Health’s growth and expansion. His expertise in operations, payor contracting, and physician relations will be pivotal as the company continues to strengthen its healthcare delivery model and expand its national presence.

Clinigence Holdings Faces Derivative Action Lawsuit

On September 8, 2025, a derivative action was filed on behalf of Nutex Health Inc. in the U.S. District Court for the Southern District of Texas. The lawsuit names the company’s CEO, CFO, President, and current and former board members as defendants, alleging violations of the Securities Exchange Act, breaches of fiduciary duties, and other misconduct. The action seeks damages, restitution, and corporate governance reforms. Nutex Health is currently unable to predict the litigation’s outcome or its financial impact.